BAMATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bamate, and what generic alternatives are available?
Bamate is a drug marketed by Alra and is included in one NDA.
The generic ingredient in BAMATE is meprobamate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the meprobamate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bamate
A generic version of BAMATE was approved as meprobamate by INVAGEN PHARMS on February 27th, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BAMATE?
- What are the global sales for BAMATE?
- What is Average Wholesale Price for BAMATE?
Summary for BAMATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Patent Applications: | 5,668 |
| DailyMed Link: | BAMATE at DailyMed |
US Patents and Regulatory Information for BAMATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alra | BAMATE | meprobamate | TABLET;ORAL | 080380-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alra | BAMATE | meprobamate | TABLET;ORAL | 080380-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
